Abstract PR004: Phase 2 study of the PD-L1 inhibitor durvalumab and VEGFR inhibitor cediranib combination with and without PARP inhibitor olaparib in patients with recurrent ovarian cancer
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Junya Tabata, Tzu-Ting Huang, Elena Giudice, Kristen Ibanez, Jayakumar R. Nair, Kevin Conlon, Britanny Solarz, Valentina Bolanos, Stanley Lipkowitz, Bernadette Redd, Aanika Balaji. Warner, Jung-Min Lee
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4414349295
Cites:
Cited by:
Related to: